Pfizer Shares Gained 2% in Morning Trading
Tiger Newspress2022-11-01
Pfizer shares gained 2.2% in morning trading.
Pfizer Inc on Tuesday raised its full-year estimates for sales of its COVID-19 vaccine by $2 billion to $34 billion, encouraged by demand for its new bivalent booster shots.
The company maintained its full-year sales forecast for COVID-19 pill Paxlovid at $22 billion.
Pfizer and Moderna have rolled out an Omicron-tailored booster dose in Europe and the United States.
It reported third-quarter sales of $22.60 billion, beating the average analyst estimate of $21.04 billion, according to IBES data from Refinitiv.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
